Author: Bhatt, Kinal; Garimella, Radhika; Taugir, Rahima; Mehta, Isha; Jamal, Muhammad; Vijayan, Rupalakshmi; Offor, Rita; Nwankwo, Kanayo; Arif, Uroosa; Waheed, Khurram; Kumari, Priyanka; Lathiya, Maulik; Michel, George; Pandya, Naushira; Halpern, John; Nasir, Hassan; Sanchez-Gonzalez, Marcos A.
Title: Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review Cord-id: b5eanzvj Document date: 2021_3_11
ID: b5eanzvj
Snippet: Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening
Document: Hyperinflammation and cytokine storm has been noted as a poor prognostic factor in patients with severe pneumonia related to coronavirus disease 2019 (COVID-19). In COVID-19, pathogenic myeloid cell overactivation is found to be a vital mediator of damage to tissues, hypercoagulability, and the cytokine storm. These cytokines unselectively infiltrate various tissues, such as the lungs and heart, and nervous system. This cytokine storm can hence cause multi-organ dysfunction and life-threatening complications. Mavrilimumab is a monoclonal antibody (mAb) that may be helpful in some cases with COVID-19. During an inflammation, Granulocyte-macrophage colony-stimulating factor (GM-CSF) release is crucial to driving both innate and adaptive immune responses. The GM-CSF immune response is triggered when an antigen attaches to the host cell and induces the signaling pathway. Mavrilimumab antagonizes the action of GM-CSF and decreases the hyperinflammation associated with pneumonia in COVID-19, therefore strengthening the rationale that mavrilimumab when added to the standard protocol of treatment could improve the clinical outcomes in COVID-19 patients, specifically those patients with pneumonia. With this review paper, we aim to demonstrate the inhibitory effect of mavrilimumab on cytokine storms in patients with COVID-19 by reviewing published clinical trials and emphasize the importance of extensive future trials.
Search related documents:
Co phrase search for related documents- action mechanism and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- action mechanism and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- action mechanism and adaptive immune response: 1, 2, 3
- action mechanism and long term efficacy: 1, 2, 3, 4, 5, 6
- action mechanism and lung damage: 1, 2, 3, 4, 5, 6
- action mechanism and lung function: 1, 2, 3, 4, 5, 6, 7
- action mechanism and lung inflammation: 1, 2, 3, 4, 5, 6, 7
- action mechanism and lung inflammation reduce: 1
- action mechanism and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- action mechanism and macrophage activation: 1, 2
- action mechanism and macrophage function: 1
- action mechanism and macrophage neutrophil: 1
- activation recruitment and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- activation recruitment and acute respiratory distress: 1, 2, 3, 4, 5, 6, 7, 8, 9
- activation recruitment and adaptive immune response: 1, 2, 3, 4
- activation recruitment and lung destruction: 1
- activation recruitment and lung function: 1
- activation recruitment and lung inflammation: 1, 2, 3, 4, 5
- activation recruitment and macrophage activation: 1, 2, 3, 4, 5, 6, 7, 8, 9
Co phrase search for related documents, hyperlinks ordered by date